still hungry on glp-1 Why you are your GLP‑1: or not hungry enough why am i still hungry

Current UK professional guidance emphasises: Patients should inform their surgical team and anaesthetist that they are taking a GLP-1 medication as soon as surgery is planned Healthcare professionals should specifically ask about GLP-1 use during preoperative assessment, as patients may not recognise these medications as relevant to their surgery The decision to continue or pause GLP-1 therapy should be made on an individual risk-based assessment , considering the type of surgery, the specific GLP-1 agent, dose escalation status, presence of gastrointestinal symptoms, and the patient's clinical circumstances Many patients can safely continue GLP-1 medications perioperatively with appropriate precautions, while those at higher risk may benefit from temporary cessation The Summary of Product Characteristics (SmPC) for GLP-1 medications notes the delayed gastric emptying effect, which anaesthetists consider when planning perioperative care

current studies have focused primarily on wild-type p53, while the impact of hotspot p53 mutations (e.g., R175H and R273H) on ferroptosis susceptibility, and whether mutant p53 retains or rewires the dual regulatory function, is unknown

Avoid placing your pen in the door, where temperature fluctuates more

Fonseca V, Madsbad S, Falahati, Zychma MJ, Plutzky J

However, critical evaluation requires acknowledging limitations: many studies lack the sample sizes and rigorous controls standard for Western regulatory purposes, independent replication has been limited, and long-term safety data in large human cohorts is lacking